Biblio
Export 537 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is N [Clear All Filters]
“Clinical and Imaging Determinants of Neurocognitive Disorders in Post-Acute COVID-19 Patients with Cognitive Complaints.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1239-1250, 2022.
, “Clinical and Imaging Determinants of Neurocognitive Disorders in Post-Acute COVID-19 Patients with Cognitive Complaints.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1239-1250, 2022.
, “Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 893-901, 2022.
, “Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders.”, J Alzheimers Dis, vol. 88, no. 2, pp. 537-547, 2022.
, “Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders.”, J Alzheimers Dis, vol. 88, no. 2, pp. 537-547, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences.”, J Alzheimers Dis, vol. 88, no. 2, pp. 399-416, 2022.
, “Detecting Alzheimer's Disease Using Natural Language Processing of Referential Communication Task Transcripts.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1385-1398, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1195-1204, 2022.
, “Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 85, no. 3, pp. 975-992, 2022.
, “Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 85, no. 3, pp. 975-992, 2022.
, “Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis.”, J Alzheimers Dis, vol. 87, no. 1, pp. 285-304, 2022.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1451-1460, 2022.
, “Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study.”, J Alzheimers Dis, vol. 87, no. 1, pp. 211-222, 2022.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
,